Used in research and therapeutic development for diseases involving fibrosis and tissue remodeling, particularly in the kidneys, lungs, and liver. This antibody targets Gremlin-1, a protein that plays a key role in activating the TGF-β signaling pathway, which drives fibrotic processes. By inhibiting Gremlin-1, it helps reduce extracellular matrix accumulation and myofibroblast activation, making it a candidate for treating conditions such as diabetic nephropathy, idiopathic pulmonary fibrosis, and liver cirrhosis. It is also investigated in oncology due to Gremlin-1's involvement in tumor angiogenesis and cancer progression. The antibody serves as a reference tool in assay development, target validation, and preclinical studies aimed at blocking pathogenic Gremlin-1 activity.